Just another Network site

The CEO of a biotech startup with a $12 billion valuation explains why he didn’t look to Silicon Valley for backing

  • The CEO of a biotech startup with a $12 billion valuation explains why he didn’t look to Silicon Valley for backing
  • The startup has already reportedly reached a $12 billion valuation, much higher than most early-stage biotech companies.
  • The company’s technology targets certain proteins that scientists think play a critical role in the development and renewal of stem cells , the type of cells that give rise to other types of specialised cells, from eye cells to skin and hair cells.

Read the full article, click here.


@MissTechSpec: “The CEO of a biotech startup with a $12 billion valuation explains why he didn’t look to Silicon Valley for backing”


Samumed is working on treatments to regenerate…


The CEO of a biotech startup with a $12 billion valuation explains why he didn’t look to Silicon Valley for backing | Business Insider

Comments are closed, but trackbacks and pingbacks are open.